Inositol Derivatives for Use in Pathological Crystallization

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes new inositol derivatives that are chemically modified to have increased solubility, particularly by attaching polyethylene glycol groups. These modified compounds are intended for the treatment or prevention of diseases that involve abnormal calcium crystallization in the body, such as cardiovascular calcifications and kidney stones.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment or prevention of cardiovascular calcifications to reduce the risk of heart disease
• Therapy for patients with nephrocalcinosis (abnormal calcium deposits in the kidneys)
• Prevention or alleviation of kidney stones formation
• Management of calcinosis cutis (calcium deposits in the skin)
• Treatment of chondrocalcinosis (calcium deposits in cartilage)

BenefitsContent extracted from patent full text and abstract with AI.

• Improved solubility and bioavailability of inositol derivatives due to polyethylene glycol modification
• Targeted approach for preventing and treating a range of calcium-related pathological conditions
• Potential to reduce the risk of complications from diseases caused by calcium crystallization
• Versatile application across several organ systems (heart, kidneys, skin, joints)
• Novel therapeutic options for conditions with limited current treatment options

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.